Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 27, 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), a biopharmaceutical company focused on the needs of patients with severe bacterial and fungal infections, today announced that the European Commission (EC) has expanded the indications for the antifungal Cresemba.® (isavuconazole) for pediatric patients and an […]